How Psychedelics Helped with Mental Health During COVID
Study from Imperial College London reveals that the use of psychedelics during the COVID-19 pandemic was associated with improvement in symptoms of anxiety and depression, even outside of controlled therapeutic contexts
During the solitary journey that was the COVID-19 pandemic, marked by uncertainties, losses, and isolation, many people sought alternative ways to maintain emotional balance. A study conducted by researchers from Imperial College London sheds light on a phenomenon: psychedelics, which even outside clinical contexts, were associated with improvement in symptoms of anxiety, depression, and overall mental health during the most critical years of the pandemic.
Psychedelics and Emotional Resilience in Dark Times
Based on data from over 377,000 people between December 2019 and March 2022, the study investigated how the use of various substances impacted the mental health of the UK population. The group that used psychedelics in combination with cannabis showed a positive evolution, with significant improvement in depression and anxiety indicators over time, to the point of reaching scores similar to those who did not use any drugs.
"Those who used psychedelics may have experienced some improvements in mental health during the pandemic period, which supports the idea that the beneficial effects on mood and anxiety associated with these substances may extend beyond controlled conditions," the authors state.
More than substances, context matters
Contrary to what was observed in users of cannabis alone, whose levels of mental health remained low throughout the analyzed period, the group that combined psychedelics with cannabis showed progressive improvement. The researchers suggest that this may be related to the nature of psychedelics, which are deeply influenced by the emotional and social context in which they are used.
The use of psychedelics, often associated with introspective and transformative experiences, may have provided psychological support in a moment of global crisis. However, the authors themselves caution about the limitations of the study, which was completely automated and did not collect data on dosage, frequency, or context of use, fundamental aspects to understand the real effects of these substances.
The Rebirth of Psychedelics in Science
This study adds to a growing wave of research that repositions psychedelics as powerful therapeutic tools. LSD, psilocybin (the active ingredient in "magic mushrooms"), and other substances are being tested, with promising results in the treatment of treatment-resistant depression, alcoholism, and tobacco dependence.
Learn More - Psychedelics reduce neuroinflammation and show therapeutic potential, according to Brazilian researchers
In the United States, the National Institute on Drug Abuse (NIDA) allocated $1.5 million for studies on psychedelics and substance use disorders. The National Center for Complementary and Integrative Health (NCCIH) has officially recognized the therapeutic potential of psilocybin for treating alcoholism, despite the substance still being classified as illegal.
A New Perspective on Mental Health
The pandemic has exposed the urgency of more compassionate and effective approaches to mental health care, and psychedelics seem to be gaining a voice in this new chorus. Although caution and more research are needed to understand all the risks and benefits, evidence suggests that these substances, far from being mere escapism, can be allies in the emotional reconstruction of those going through deep crises.
Read Also - Psychedelics may enhance meditation in some cases, indicates new study
Perhaps what the study teaches us, in the end, is that in moments of collective pain, healing can emerge from paths that once seemed forbidden or, at least, misunderstood.
With information from Marijuana Moment.